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Abstract
Accurate measurement of sedentary time and physical activity (PA) is essential to establish their relationships with rheu-
matoid arthritis (RA) outcomes. Study objectives were to: (1) validate the GT3X+ and  activPAL3μ™, and develop RA-
specific accelerometer (count-based) cut-points for measuring sedentary time, light-intensity PA and moderate-intensity PA 
(laboratory-validation); (2) determine the accuracy of the RA-specific (vs. non-RA) cut-points, for estimating free-living 
sedentary time in RA (field-validation). Laboratory-validation: RA patients (n = 22) were fitted with a GT3X+,  activPAL3μ™ 
and indirect calorimeter. Whilst being video-recorded, participants undertook 11 activities, comprising sedentary, light-
intensity and moderate-intensity behaviours. Criterion standards for devices were indirect calorimetry (GT3X+) and direct 
observation  (activPAL3μ™). Field-validation: RA patients (n = 100) wore a GT3X+ and  activPAL3μ™ for 7 days. The 
criterion standard for sedentary time cut-points (RA-specific vs. non-RA) was the  activPAL3μ™. Results of the laboratory-
validation: GT3X—receiver operating characteristic curves generated RA-specific cut-points (counts/min) for: sedentary 
time = ≤ 244; light-intensity PA = 245–2501; moderate-intensity PA ≥ 2502 (all sensitivity ≥ 0.87 and 1-specificity ≤ 0.11). 
 ActivPAL3μ™—Bland–Altman 95% limits of agreement (lower–upper [min]) were: sedentary = (− 0.1 to 0.2); standing 
= (− 0.7 to 1.1); stepping = (− 1.2 to 0.6). Results of the field-validation: compared to the  activPAL3μ™, Bland–Altman 
95% limits of agreement (lower–upper) for sedentary time (min/day) estimated by the RA-specific cut-point = (− 42.6 
to 318.0) vs. the non-RA cut-point = (− 19.6 to 432.0). In conclusion, the  activPAL3μ™ accurately quantifies sedentary, 
standing and stepping time in RA. The RA-specific cut-points offer a validated measure of sedentary time, light-intensity 
PA and moderate-intensity PA in these patients, and demonstrated superior accuracy for estimating free-living sedentary 
time, compared to non-RA cut-points.
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Introduction
Research evidence supports the benefits of physical activ-
ity (PA) for improving health-related outcomes among 
people with rheumatoid arthritis (RA) [1]. More recently, 
studies also suggest sedentary behaviour (waking behav-
iour ≤ 1.5 metabolic equivalents [METs], whilst in a sit-
ting, reclining or lying posture) [2, 3] is adversely asso-
ciated with RA outcomes [4]. However, most evidence 
regarding the role of sedentary time and PA in RA is based 
on studies employing self-report methods to quantify 
engagement in these behaviours [4, 5].
Device-based assessments of sedentary time and PA 
offer a more objective measure of behaviour, and have 
demonstrated higher validity and reliability relative to 
self-report instruments [6-8]. Consequently, devices are 
being more readily used to measure sedentary time and PA 
in different populations, including in RA [4, 9]. Currently, 
hip-worn accelerometers (e.g., ActiGraph [Florida, USA]) 
are the most commonly employed device in RA studies 
to estimate the frequency, intensity and duration of free-
living behaviour. The accelerometer records and stores raw 
acceleration data (g), which is subsequently processed to 
provide estimates of sedentary behaviour and PA. Cur-
rently, several processing methods can be applied to raw 
accelerometer data, with the dominant approach being the 
use of thresholds or ‘cut-points’ that classify behaviour as 
sedentary, light-intensity PA (LPA), moderate-intensity 
PA (MPA) or vigorous-intensity PA. There is an absence 
of a consensus on the ‘best’ method, with this decision 
dependent on the research question, study resources and 
research team expertise [10].
A popular and widely accessible data processing 
method generates sedentary time and PA estimates by 
applying cut-points to accelerometer activity counts 
(‘count-based cut-points’) that have been derived from 
raw accelerometer data using the device manufacturer’s 
proprietary software. These count-based cut-points are 
commonly employed, largely due to intuitive and easy-to-
use software platforms that facilitate straightforward pro-
cessing and analysis of complex raw accelerometer data, 
thus, making the application of accelerometry accessible 
to researchers from a wide range of disciplines (e.g., clini-
cal/medicine, exercise science, behavioural science). How-
ever, whilst the advantages of accelerometry (and specifi-
cally, count-based cut-points) to measure sedentary time 
and PA are being increasingly recognised by RA research-
ers, several limitations exist regarding their application in 
this patient group.
First, few accelerometers have been specifically vali-
dated for measurement of sedentary time and PA in 
RA (e.g., against indirect calorimetry). Consequently, 
existing RA studies employing accelerometers have largely 
employed count-based cut-points developed in validation 
studies of healthy participants [11, 12] to quantify seden-
tary time and PA in RA. However, as RA patients differ 
markedly to people without RA in terms of physiology, 
physical function and associated activity patterns (e.g., RA 
patients demand a relatively higher basal metabolic rate 
compared to the general population [13]), such sedentary 
time and PA estimates should be interpreted with caution.
Second, most existing count-based cut-points are uni-
axial, generating sedentary time and PA estimates using 
data captured by a single axis of movement. Technologi-
cal advancements are such that triaxial accelerometers are 
now common place, and can capture data across three axes 
(Y, X and Z) to provide a more valid assessment of behav-
iour [14]. Thus, given the increasing popularity of applying 
count-based cut-points to examine sedentary time and PA in 
RA studies, there is a critical need to develop RA-specific 
triaxial accelerometer count-based cut-points to provide a 
valid and accessible accelerometer data processing method 
for RA researchers.
Still, a key limitation of accelerometers is their inability 
to distinguish sitting (sedentary behaviour) from standing 
without movement (LPA). Specifically, accelerometers work 
on the basis that all movements registered below a ‘seden-
tary time cut-point’ are by default, classed as sedentary [15]. 
However, low-movement behaviours may occur in a sitting 
or standing posture, but both may record accelerations that 
register below the ‘sedentary time cut-point’. Thus, acceler-
ometers may lead to an overestimation of sedentary time by 
misclassifying low-movement standing behaviours as sitting 
(sedentary). The activPAL™ (PAL Technologies, Glasgow, 
UK) addresses this limitation, and is able to accurately clas-
sify behaviours as sitting/lying (sedentary), standing or step-
ping. This device is currently considered the gold standard 
for measurement of free-living sedentary time [6]. Thus, 
the activPAL™ primarily offers a measure of sedentary 
behaviour, rather than frequency, intensity and duration of 
PA. Consequently, few RA studies have employed the activ-
PAL™, with extant research employing this device focusing 
specifically on the role of sedentary behaviour [16].
Considering exponential growth in research centred on 
the role of sedentary behaviour and PA for improving RA 
disease outcomes, it is critical that device-based measures 
are properly validated for use in this population. There-
fore, the overarching aim of the current study was to vali-
date the commonly employed ActiGraph GT3X+ and the 
 activPAL3μ™, for measurement of sedentary time and PA 
in RA. In a laboratory-validation (objective 1), this study 
aimed to: (a) validate the GT3X+ against indirect calo-
rimetry to generate RA-specific triaxial (vector magnitude 
[VM]) accelerometer count-based cut-points for sedentary 
time, LPA and MPA; (b) validate the  activPAL3μ™ against 
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direct observation for measurement of sedentary, standing 
and stepping time. Then, using these data, conduct a field-
validation (objective 2) to compare the validity of the new 
RA-specific triaxial sedentary time count-based cut-point vs. 
a widely used non-RA uniaxial sedentary time count-based 
cut-point (< 100 counts/min) [11, 12] for measurement of 
free-living sedentary time in RA, against the gold standard 
 (activPAL3μ™).
Materials and methods
Participants and recruitment
Participants were recruited from outpatient clinics at Rus-
sells Hall Hospital (Dudley Group NHS Foundation Trust). 
The only requirements for inclusion in this study were a 
clinical diagnosis of RA according to the American College 
of Rheumatology/European League Against Rheumatism 
classification criteria [17], and aged ≥ 18 years. For objec-
tive 1, patients were required to ambulate independently. 
For objective 2, patients were eligible if they could ambu-
late independently, or with an assistive device. Participants 
were excluded from objectives 1 and 2 if they were preg-
nant. Eligibility criteria were intentionally broad in order 
that the GT3X+ and  activPAL3μ™ were validated in a more 
diverse population of people living with RA (e.g., males 
and females; low, moderate and high disease activity). All 
participants provided written informed consent. This study 
was approved by the local National Health Service Research 
Ethics Committee (16/WM/0371).
Protocol
The protocol for this study has been previously published 
[18], but methods and analytical approaches are briefly 
described herein.
Objective 1 (laboratory‑validation)
Participants (n = 22) reported to the laboratory following a 
12-h fast, and having refrained from exercise for 48 h. Upon 
arrival, participants completed physical assessments (e.g., 
height, weight, body-mass index), and underwent routine 
clinical evaluations to determine their disease activity (dis-
ease activity score-28 [19]) and level of functional disabil-
ity (health assessment questionnaire [20]). Participants were 
then fitted with the GT3X+,  activPAL3μ™, heart rate moni-
tor (Polar Electro Oy Ltd., Kempele, Finland) and Cortex 
Metalyzer® 3B (indirect calorimeter [Cortex Biophysik, 
Leipzig, Germany]) for the duration of the laboratory-vali-
dation. For direct observation of behaviour, a video camera 
was set up overlooking the laboratory. All equipment was 
time-synchronised.
Participants undertook 11 activities (6 standardised 
activities and 5 activities of daily living [ADLs]). Activities 
required between 1.3 and 3.5 METs (ranging from sedentary 
behaviour to MPA) and were 6-min in duration [21]. Five-
min rest periods separated the ADLs, to allow heart rate and 
VO2 to return to resting levels [14, 21, 22].
Objective 2 (field‑validation)
Participants (n = 104) attended the laboratory to complete 
physical assessments and routine clinical evaluations, as per 
objective 1. Participants were asked to wear the GT3X+ and 
 activPAL3μ™ for 7 days to assess free-living sedentary time 
and PA [23]. The GT3X+  was worn during all waking hours, 
removing for water-based activities. The  activPAL3μ™ was 
worn continuously for 24 h/day.
Measures
Devices
The GT3X+ is a triaxial accelerometer that records accel-
erations on three axes (vertical [Y], horizontal right-left [X] 
and horizontal front-back [Z]), over researcher-defined time 
periods (epochs). These data are used to compute VM [VM 
= √(axisY2 + axisX2 + axisZ2)], which is used to quantify 
sedentary time and PA. The GT3X+ accelerometers were 
set to sample movement in 1-s epochs at a rate of 30 Hz. For 
objectives 1 and 2, participants wore the GT3X+ attached to 
an elastic belt on their right hip [12, 22, 24, 25].
The  activPAL3μ™ is an accelerometer with inclinometer 
function, that measures free-living behaviour over consecu-
tive 24-h periods. For objectives 1 and 2, the  activPAL3μ™ 
was worn in a mid-anterior position on the right thigh, 
attached with a waterproof adhesive dressing [26].
Criterion standards
Indirect calorimetry was the criterion standard for validating 
the GT3X+. The Cortex Metalyzer® 3B uses a breath-by-
breath system to directly measure an individual’s concen-
tration of inspired oxygen  (O2) and expired carbon diox-
ide  (CO2) to calculate VO2 (ml/kg/min) and METs, using 
 MetaSoft® (Cortex Biophysik). Direct observation (via 
video camera) was the criterion standard for validating the 
 activPAL3μ™.
Following laboratory-validation of the  activPAL3μ™, this 
device was employed as the criterion standard for assess-
ing the accuracy of the RA-specific triaxial vs. the non-RA 
uniaxial sedentary time count-based cut-point. This decision 
was based on prior studies demonstrating high validity of the 
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 activPAL3μ™ for estimating free-living sedentary time in 
RA, recognising this device as the current gold standard for 
measurement of free-living sedentary time [6].
Data reduction and statistical analysis
Objective 1 (laboratory‑validation)
GT3X+ and indirect calorimetry
The manufacturer’s software (Actilife [ActiGraph]) was 
used to download time-stamped GT3X+ data in the format 
of triaxial (VM) activity counts. Data were downloaded in 
counts/s, and converted to counts/min for analysis.
Metasoft® was used to download and export breath-by-
breath VO2 data from the Cortex  Metalyzer® 3B. In Micro-
soft Excel, second-by-second VO2 data were averaged across 
each minute to compute average VO2 (ml/kg/min) per min-
ute of activity. These data were graphed to identify when 
steady-state VO2 was achieved within each activity (steady-
state = variation within ± 0.5 ml/kg/min). Graphed data 
indicated steady-state occurred in min 4–6 of each activity 
(the final 2 min of the 11 activities). VO2 (ml/kg/min) and 
GT3X+ (counts/min) data were therefore averaged across 
min 4–6 of each laboratory testing component, to provide 
steady-state VO2 and GT3X+ data for each activity. These 
data were exported into SPSS (Chicago, USA, v.24) for sta-
tistical analysis. Where participants did not reach steady-
state VO2 during an activity, their data recorded for that 
particular activity were excluded.
Statistical analysis Average (steady-state) VO2 data were 
converted into METs (1  MET = 3.5  ml/kg/min) and then 
classified as sedentary (≤ 1.5 METs), LPA (1.6–2.9 METs) 
or MPA (≥ 3 METs). Using these classifications, data 
were recoded to create binary variables for use in receiver 
operating characteristic (ROC) curve analysis, to define 
RA-specific triaxial (VM) accelerometer count-based cut-
points for sedentary time, LPA and MPA. Specifically, 
data were recoded as sedentary/not sedentary or MPA/not 
MPA using binary indicators (1/0). ROC curves identi-
fied the VM activity count maximising sensitivity (Y-axis) 
and specificity (X-axis) for correctly classifying behaviour 
as sedentary or MPA. Area under the curve (AUC) values 
were also calculated (AUC criteria: 0.90–1.00 = excellent; 
0.80–0.89 = good; 0.70–0.79 = fair; 0.60–0.69 = poor; < 
0.60 = failure).
ActivPAL3μ™ and direct observation
PAL Connect (PAL Technologies) was used to download 
and export  activPAL3μ™ time-stamped data to Microsoft 
Excel. Outputs displayed sedentary, standing and step-
ping time, and number of steps and sit-stand transitions, 
for consecutive 15-s periods for the duration of the lab-
oratory-validation. For direct observation, the researcher 
observed all video camera recordings, recording engage-
ment in sitting/lying (sedentary), standing or stepping, as 
well as counting steps and sit-stand transitions, every 15 s 
for each activity.
Statistical analysis Means (M) and standard devia-
tions (SD) were calculated for  activPAL3μ™-assessed 
and directly observed sedentary, standing and stepping 
time (min), and steps and sit-stand transitions (number). 
Bland–Altman analysis calculated 95% limits of agreement 
(LOA [lower  to  upper]) between  activPAL3μ™-assessed 
vs. directly observed behaviours, using the M and SD 
of the differences (min) between the two measures 
[M ± (SD × 1.96)] [27, 28]. Finally, percentage accuracy for 
 activPAL3μ™-assessment vs. direct observation of behav-
iours was computed [% accuracy = (activPAL3μ™ value/
direct observation value) × 100].
Objective 2 (field‑validation)
Actilife was used to download 7-day GT3X+ data (1-s 
epochs) and check non-wear (criteria = ≥ 60 min of con-
secutive zero counts, spike tolerance of 2 min) [9, 12]. All 
non-wear periods identified were excluded from each par-
ticipant’s data file. After removing non-wear periods, par-
ticipants’ 7-day GT3X+ data were retained for inclusion 
in statistical analysis where GT3X+ accelerometers were 
worn for ≥ 10 h/day on ≥ 4 days (including ≥ 1 weekend 
day) [9, 12]. The RA-specific triaxial (VM) accelerometer 
count-based cut-point (developed in objective 1) and non-
RA uniaxial (Y-axis) accelerometer count-based cut-point 
(< 100 counts/min) [11, 12], were then applied to 7-day 
GT3X+ data to derive estimates of free-living sedentary 
time (min/day).
For the  activPAL3μ™, PAL Connect was used 
to download and export daily movement data (15-s 
epochs) that corresponded to valid days measured via 
the GT3X+ . Sleep time was manually removed from 
 activPAL3μ™ data using wear-time logbooks and sleep-
periods identified from GT3X+ data analysis. Estimates 
of free-living  activPAL3μ™-assessed sedentary time 
(min/day) were calculated using PAL Connect propri-
etary algorithms.
Statistical analysis For objective 2, Bland–Altman 
analysis was used to calculate 95% LOA (lower to upper) 
between GT3X+- and  activPAL3μ™-assessed free-living 
sedentary time, for both RA-specific and non-RA count-
based cut-points. LOA were determined using the M 
and SD of the differences (min/day) between estimates 
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of GT3X +- and  activPAL3μ™-assessed sedentary time 
[M ± (SD × 1.96)].
Results
Objective 1 (laboratory‑validation)
Twenty-two patients (86% female, n = 19) participated in the 
laboratory protocol (Table 1). GT3X+ and indirect calorim-
etry: Table 2 reports the M (SD) for GT3X+ activity counts 
and METs during steady-state VO2. Activity intensities 
(METs) reflecting sedentary, LPA and MPA were achieved 
as intended. Table 3 reports results of ROC curve analysis 
and the RA-specific triaxial (VM) accelerometer count-
based cut-points maximising sensitivity and specificity. The 
AUC demonstrated ‘excellent’ fit for RA-specific sedentary 
time (AUC = 1.00) and MPA (AUC = 0.94) count-based 
cut-points. ActivPAL3μ™ and direct observation: Table 4 
reports the M (SD) for  activPAL3μ™-assessed and directly 
observed behaviours during the laboratory testing proce-
dure. Compared to direct observation, the  activPAL3μ™ 
accurately classified sedentary, standing and stepping time, 
and step number, > 98% of the time. For number of sit-stand 
transitions, classification accuracy was 72%.   
Mean differences for  activPAL3μ™-assessed vs. directly 
observed behaviours were computed (M [SD]): seden-
tary time = 0.1 (0.1) min; standing = 0.2 (0.5) min; step-
ping = − 0.3 (0.5) min; steps = − 30 (44); sit-stand transi-
tions = − 2 (1). Bland–Altman analysis (Fig. 1) demonstrated 
narrow 95% LOA (lower to upper) for sedentary (− 0.1 to 
0.2), standing (− 0.7 to 1.1) and stepping (− 1.2 to 0.6) time 
(min). For number of steps, 95% LOA were wider (− 116 
to 57). As only M (SD) = 5 (1) and M (SD) = 7 (0) sit-stand 
transitions were recorded by the  activPAL3μ™ and direct 
observation, respectively, Bland–Altman plots could not be 
produced for this outcome.
Objective 2 (field‑validation)
A total  of n = 100 participants (96%  [71% female, n = 
71]) provided valid 7-day GT3X+ and corresponding 
 activPAL3μ™ data (Table 1). GT3X+-derived sedentary 
time estimates (M [SD]) were: RA-specific count-based 
cut-point = 686.1 (72.4) min/day vs. non-RA count-based 
cut-point = 754.7 (62.5) min/day.
For the RA-specific count-based cut-point (≤ 244 counts/
min) vs. the  activPAL3μ™, Bland–Altman analysis (Fig. 2) 
revealed a mean difference of 137.7 (SD = 92.0), with 95% 
LOA (lower to upper) = (− 42.6 to 318.0), for sedentary time 
(min/day). Most data points were positioned above zero and 
followed a downward trend, whereby a lower mean differ-
ence between measures was observed at higher levels of 
sedentary time.
Compared to the RA-specific triaxial count-based cut-
point, the non-RA uniaxial count-based cut-point demon-
strated a greater mean difference (206.2 [SD = 115.2]) and 
Table 1  Objectives 1 and 2: participant characteristics
M (SD) shown for age, BMI, height, weight, body fat percentage, 
RA duration, DAS-28 and HAQ score. DAS-28 was calculated using 
erythrocyte sedimentation rate, 28 swollen-and-tender joint count and 
visual analogue scale (overall health from 0 [very good] to 100 [very 
poor]). HAQ scores were defined as, ability to undertake activities of 
daily living (0, without any difficulty; 1, with some difficulty; 2, with 
much difficulty; 3, unable to do)
BMI body-mass index, RA rheumatoid arthritis, DAS-28 disease 
activity score-28, HAQ health assessment questionnaire
Objective 1 Objective 2
Age (years) 53.7 (12.5) 58.5 (12.1)
BMI (kg/m2) 27.4 (5.7) 28.9 (6.1)
Height (m) 1.7 (0.1) 1.6 (0.1)
Weight (kg) 74.9 (18.0) 80.0 (20.5)
Body fat (%) 34.6 (9.3) 35.6 (8.5)
RA duration (years) 6.7 (6.3) 10.6 (10.5)
DAS-28 3.2 (1.7) 4.0 (1.5)
HAQ 0.8 (0.6) 1.2 (0.8)
Table 2  Objective 1: descriptive statistics for laboratory-validation of 
the ActiGraph GT3X+
MET values (compendium of physical activities [35]) are specified 
next to each activity. M (SD) are shown for GT3X+ activity counts 
(VM) and METs, averaged across min 4–6 of each activity. Number 
of participants (n) included in analysis are shown per activity
METs metabolic equivalents, VM vector magnitude
Activity (METs) n GT3X+ (VM 
activity counts/
min)
Energy 
expenditure 
(METs)
Standardised testing component 1
 Lying (1.3) 20 0 (0) 0.6 (0.2)
 Sitting (1.3) 22 0 (0) 0.7 (0.2)
 Standing (1.3) 18 141 (45) 0.8 (0.2)
Activities of daily living
 Reading a newspaper (1.3) 19 7 (13) 0.8 (0.2)
 Washing and drying dishes 
(1.8)
15 518 (315) 1.8 (0.3)
 Ironing and folding clothes 
(2.0)
12 549 (279) 1.9 (0.3)
 Placing bed linens on pil-
lows and duvet (2.5)
18 1051 (526) 2.3 (0.5)
 Sweeping the floor (3.3) 17 1675 (502) 2.3 (0.6)
Standardised testing component 2
 Walking at 3.2 km/h (2.8) 19 2148 (571) 2.7 (0.7)
 Walking at 4 km/h (3.0) 20 3120 (637) 3.2 (0.8)
 Walking at 4.8 km/h (3.5) 18 3944 (882) 3.4 (0.4)
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wider 95% LOA (lower to upper) = (− 19.6 to 432.0) vs. the 
 activPAL3μ™ for sedentary time (min/day). Bland–Altman 
analysis for the non-RA count-based cut-point revealed most 
data points were scattered above zero, and a downward trend 
was observed (lower mean difference between measures at 
higher levels of sedentary time).
Discussion
The current study validated the ActiGraph GT3X+ and 
 activPAL3μ™—two devices commonly used in sedentary 
behaviour and PA research—for measurement of sedentary 
time and PA in people living with RA. Whilst there are sev-
eral options for processing raw accelerometer data to quan-
tify sedentary time and PA in healthy populations, count-
based cut-points offer an accessible means of accelerometer 
data processing for researchers and health professionals 
working in rheumatology. To date, RA studies employing 
accelerometers have largely relied on the application of non-
RA count-based cut-points to quantify free-living sedentary 
time and PA in this population [29, 30], which are limited in 
their validity when we consider the unique physiology and 
associated movement patterns of people living with RA [21, 
22, 24]. Thus, there exists a critical need for the development 
of RA-specific count-based cut-points, which can be easily 
and consistently employed across RA studies.
In response, this is the first study to calibrate the com-
monly employed GT3X+ and define RA-specific triaxial 
accelerometer count-based cut-points, for valid measurement 
of sedentary time, LPA and MPA in RA. Our RA-specific 
count-based cut-points were derived according to energy 
requirements of behaviour among people with RA, and dem-
onstrated high sensitivity and specificity for classification of 
sedentary time, LPA and MPA. Thus, the application of our 
novel RA-specific triaxial count-based cut-points are likely 
to provide more valid assessments of sedentary time and PA 
in RA, relative to employing non-RA uniaxial count-based 
cut-points developed in validation studies of healthy adults. 
We therefore recommend using the RA-specific count-based 
cut-points proposed herein, in future RA research.
This study also assessed the accuracy of the  activPAL3μ™ 
for measurement of sedentary, standing and stepping time in 
RA. Only one study has examined the ability of the activ-
PAL™ to validly assess posture in RA [31]. Larkin et al. 
[31] employed regression analysis and observed strong asso-
ciations between activPAL™-assessed sedentary, standing 
and stepping time with directly observed behaviour. How-
ever, it would be surprising to find a non-significant relation-
ship between two methods designed to measure the same 
variables [27, 28]. Thus, we employed Bland–Altman analy-
sis to determine agreement between  activPAL3μ™-assessed 
vs. directly observed behaviours [27, 32], and reported high 
classification accuracy (> 98%) between the two measures 
for all behaviours, in our sample of RA patients. This is in 
line with past research in non-RA populations [26, 33] and 
Table 3  Objective 1: ROC 
curve-generated RA-specific 
triaxial (VM) accelerometer 
count-based cut-points
RA-specific count-based cut-points were developed for sedentary time, LPA and MPA, based on average 
GT3X+ activity counts (VM) and METs during steady-state VO2 (± 0.5 ml/min/kg [min 4–6 of each activ-
ity]). LPA count-based cut-points were defined using the upper cut-point threshold of sedentary time and 
the lower cut-point threshold of MPA. AUC demonstrated accuracy of the RA-specific count-based cut-
points (0.90–1.00 = excellent; 0.80–0.89 = good; 0.70–0.79 = fair; 0.60–0.69 = poor; < 0.60 = failure)
RA rheumatoid arthritis, VM vector magnitude, AUC area under the curve, LPA light-intensity physical 
activity, MPA moderate-intensity physical activity, – does not apply
Epoch (1-min) RA-specific count-based cut-points 
(VM activity counts/min)
Sensitivity 1-Specificity AUC 
Sedentary time  ≤ 244 0.99 0.03 1.00
LPA  > 244–< 2502 – – –
MPA  ≥ 2502 0.87 0.11 0.94
Table 4  Objective 1: descriptive statistics for laboratory-validation of 
the  activPAL3μ™
M (SD) are shown for total  activPAL3μ™-assessed and directly 
observed time spent sedentary, standing and stepping (total min), 
and number of steps and sit-stand transitions, during each activ-
ity of the laboratory protocol. The percentage accuracy for 
 activPAL3μ™-assessment vs. direct observation of each behaviour 
is also shown [% accuracy = (activPAL3μ™ value/direct observation 
value) × 100]
ActivPAL3μ™ Direct observa-
tion
Accuracy (%)
Sedentary (total 
min)
18.1 (0.1) 18.0 (0.0) 99.6
Standing (total 
min)
29.2 (0.8) 28.9 (0.6) 99.2
Stepping (total 
min)
18.8 (0.8) 19.1 (0.6) 98.4
Steps (total 
number)
2044 (122) 2074 (144) 98.6
Sit-stand transi-
tions (total 
number)
5 (1) 7 (0) 72.1
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further supports the recommendation that the activPAL™ be 
considered the gold standard for assessment of free-living 
sedentary time [6], including in RA.
On the basis of this recommendation, we examined the 
validity of the RA-specific sedentary time count-based cut-
point, using the  activPAL3μ™ as the criterion standard. 
Results revealed a mean difference of 2.3 h/day between 
sedentary time quantified using the RA-specific count-based 
cut-point vs. the  activPAL3μ™. Bland–Altman plots demon-
strated most data points to fall above zero, suggesting over-
estimation of sedentary time using the RA-specific count-
based cut-point, compared to the  activPAL3μ™. Still, when 
compared to the  activPAL3μ™, our RA-specific count-based 
cut-point produced a smaller mean difference, and narrower 
95% LOA, relative to the commonly used non-RA count-
based cut-point (< 100 counts/min) [11, 12].
It is possible that the observed lack of agreement between 
sedentary time quantified using the RA-specific count-
based cut-point vs.  activPAL3μ™-assessed sedentary 
time in this study reflects the inability of accelerometers 
to differentiate between sitting and standing, rather than 
relatively compromised validity of the RA-specific count-
based cut-point described herein. Our data support this as 
a plausible explanation for two reasons. First, participants’ 
average MET value during ‘standing’ in the laboratory pro-
tocol was 0.8 METs (< the 1.5 METs used to define seden-
tary behaviour). Second, the downward trend observed in 
Bland–Altman plots suggests agreement between GT3X+- 
and  activPAL3μ™-assessed sedentary time improves at 
higher levels of sedentary time, where lower levels of PA 
(including standing) are likely to occur. That is, for peo-
ple engaging in high levels of sedentary time, standing 
may occupy less of daily waking behaviour and, therefore, 
there is less opportunity to misclassify standing time as 
sedentary time. In a recent study comparing accelerom-
eter- and activPAL™-assessed sedentary time in older 
adults, Aguilar-Farías et al. [24] demonstrated that their 
population-specific sedentary time VM count-based cut-
points (e.g., < 60 counts/min) were better able to detect 
combined activPAL™-assessed sedentary and standing time 
Mean: sedentary (min)
18.1018.0518.00
1.00
.50
.00
-.50
-1.00
a
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30.0029.0028.0027.00
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1.00
.00
-1.00
-2.00
-3.00
-4.00
-5.00
b
Mean: stepping (min)
21.0020.0019.0018.00
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4.00
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2.00
1.00
.00
-1.00
-2.00
-3.00
-4.00
-5.00
c
Mean: steps (number)
2400.002300.002200.002100.002000.001900.001800.00
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d
Fig. 1  Objective 1: Bland–Altman plots showing agreement (mean 
difference and 95% limits of agreement [LOA]) for time spent sed-
entary (a), standing (b), and stepping (c), as well as number of steps 
(d), between the  activPAL3μ™ vs. direct observation. Note: Straight 
full line represents mean difference and the straight dotted line repre-
sents lower and upper LOA (95%)
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(AUC = 0.82), compared to activPAL™-assessed sedentary 
time alone (AUC = 0.73).
In summary, results suggest that future studies should 
employ the  activPAL3μ™ for valid assessment of sedentary 
time in people living with RA. When this is not possible, the 
RA-specific sedentary time count-based cut-point represents 
a more valid alternative, relative to the non-RA count-based 
cut-point of < 100 counts/min [11, 12] in this population. 
However, these recommendations should be considered 
in the context of study limitations. First, the nature of the 
Fig. 2  Objective 2: Bland–Alt-
man plots showing agree-
ment (mean difference and 
limits of agreement [LOA]) 
between GT3X+-assessed 
vs.  activPAL3μ™-assessed 
sedentary time. Accelerometer 
count-based cut-points applied 
were: RA-specific (VM) count-
based cut-points [≤ 244 count/
min, derived from objective 1 
of this study (a)], and non-RA 
(Y-axis) count-based cut-points 
[< 100 counts/min (b)]. Note: 
Straight full line represents 
mean difference and the straight 
dotted line represents lower and 
upper LOA (95%)
Mean: RA-specific cut-point (sedentary min/day)
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laboratory-validation meant that a free-living environment 
could not be wholly achieved, only replicated. Still, the labo-
ratory protocol was informed by similar validation studies 
conducted in RA and non-RA populations, and included 
several activities typically undertaken in a free-living envi-
ronment [21, 31, 34]. Second, participants not reaching 
steady-state VO2 during laboratory-validation activities were 
excluded from ROC curve analysis, which reduced the num-
ber of data points available for cut-point calibration (out of 
a possible 199: sedentary time = 82; LPA = 87; MPA = 30). 
Nevertheless, the number of data points for each activity 
intensity are comparable to other studies that have developed 
accelerometer count-based cut-points for measuring seden-
tary time, LPA and MPA in populations with reduced physi-
cal function [14]. Third, participants included in both labo-
ratory- and field-based protocols were mostly females with 
moderate RA disease activity. Thus, findings may be less 
generalisable to male RA patients and those with more/less 
active disease. Future research should, therefore, confirm 
the validity of the RA-specific count-based cut-points and 
 activPAL3μ™ in different populations of RA patients (e.g., 
males, higher/lower disease activity). The current study has 
provided a ‘first step’ towards further work in this area.
Finally, the primary aim of the current study was to 
develop RA-specific triaxial accelerometer count-based cut-
points to allow researchers to easily and consistently apply 
these criteria to accelerometer data in the RA population 
with heightened accuracy, compared to non-RA (and uni-
axial) count-based cut-points. Indeed, the development of 
RA-specific count-based cut-points fills an important gap 
in the literature, providing an accessible tool for the grow-
ing number of rheumatology professionals (e.g., consultants, 
nurses, physiotherapists) conducting research to understand 
the role of sedentary time and PA in RA. However, due to a 
rapidly evolving field and technological advancements in the 
measurement of sedentary time and PA, it is important that 
future research examines the validity of other emerging ana-
lytical approaches that involve the development of complex 
data processing algorithms, to compliment the count-based 
cut-point validation model employed herein.
Conclusion
This study confirms the  activPAL3μ™ can be considered the 
gold standard for measurement of free-living sedentary time 
in RA. Further, RA-specific triaxial accelerometer count-
based cut-points presented herein are sensitive and specific 
for measurement of sedentary time, LPA and MPA, and 
permit more accurate assessment of free-living sedentary 
time compared to the commonly employed non-RA uniaxial 
accelerometer count-based cut-point [11, 12]. Thus, in the 
absence of the  activPAL3μ™, our data support use of the 
RA-specific count-based cut-point for assessment of seden-
tary time in this patient group.
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